Leveraging the Activity of Tumor Vaccines with Cytotoxic Chemotherapy
- 15 September 2005
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (18) , 8059-8064
- https://doi.org/10.1158/0008-5472.can-05-1797
Abstract
Engaging the power of the patient's own immune system to actively seek out and destroy transformed cells holds great promise for cancer therapy. Tumor vaccines offer the potential for preventing cancer in high-risk individuals, preventing disease relapse after diagnosis and initial therapy, and shifting the balance of the host-tumor interaction to mitigate the progression of advanced cancers. The therapeutic activity of tumor vaccines is limited by the sheer physical burden of the cancer itself, pathways of local immune tolerance and escape active within the tumor microenvironment, and superimposed potent systemic mechanisms of immune tolerance. In this review, we describe how cytotoxic chemotherapy can be integrated with tumor vaccines using unique doses and schedules to break down these barriers, releasing the full potential of the antitumor immune response to eradicate disease.Keywords
This publication has 37 references indexed in Scilit:
- Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamideBlood, 2005
- Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapyBlood, 2005
- Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer PatientsThe Journal of Experimental Medicine, 2004
- CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curativeEuropean Journal of Immunology, 2004
- neu Antigen-Negative Variants Can Be Generated after neu-Specific Antibody Therapy in neu Transgenic MiceCancer Research, 2004
- Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimerasBlood, 2003
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- MyD88 is involved in the signalling pathway for Taxol‐induced apoptosis and TNF‐α expression in human myelomonocytic cellsBritish Journal of Haematology, 2002
- The enemy within: keeping self-reactive T cells at bay in the peripheryNature Reviews Immunology, 2002
- The role of MyD88 and TLR4 in the LPS-mimetic activity of TaxolEuropean Journal of Immunology, 2001